National Referral Unit for Tropical Diseases, Infectious Diseases Department, Ramón y Cajal University Hospital, IRYCIS, Ctra Colmenar, Km 9,100, 28034, Madrid, Spain.
J Travel Med. 2019 Oct 14;26(7). doi: 10.1093/jtm/taz060.
Chagas disease, or American trypanosomiasis, is a protozoan infectious disease endemic throughout most of the Americas, caused by the trypanosome, Trypanosoma cruzi, and mainly transmitted to humans by reduviid or kissing bugs. Some progress has been achieved in control of the disease mainly in endemic areas, but migration flows have acted as drivers for the emergence of the disease mainly in non-endemic areas of Europe and North America. Most imported cases of Chagas disease in Europe are reported in migrants from highly endemic areas of countries such as Bolivia and Paraguay, and reports of Chagas disease in travellers are extremely rare.
Pan American Health Organization (PAHO) recently updated their guidelines on the diagnosis and management of Chagas. These guidelines and their applicability to migrants and travellers are reviewed.
PAHO recommends the use of two serological tests for diagnosis of chronic infection (allowing for the use of a single sensitive test followed by confirmation in special settings such as the screening of potential blood donors). The indication for specific trypanocidal treatment of acute infections, children and women of child-bearing age remains as before, with either benznidazole or nifurtimox being the treatment of choice. For chronic infection with/without organ damage, treatment recommendations are less well defined. Although treatment is generally not recommended in patients with visceral involvement, decisions regarding treatment need to be tailored to the individual. Either benznidazole or nifurtimox may be used for initial treatment.
The recent PAHO Guidelines provide a framework to aid the diagnosis and management of this infection, but several aspects such as the underdiagnosis of infections, the multidisciplinary approach to patient management, the investigation of novel biomarkers of disease progression/response to treatment and the development of new treatment strategies are areas which should be further strengthened.
恰加斯病,又称美洲锥虫病,是一种原生动物传染病,在美洲大部分地区流行,由锥虫,即克氏锥虫引起,主要通过吸血蝽或接吻虫传播给人类。在流行地区,该病的控制已经取得了一些进展,但移民流动成为该病在欧洲和北美非流行地区出现的驱动因素。在欧洲,大多数输入性恰加斯病病例发生在来自玻利维亚和巴拉圭等高度流行地区的移民中,旅行者中报告的恰加斯病极为罕见。
泛美卫生组织(PAHO)最近更新了其关于恰加斯病诊断和管理的指南。本文综述了这些指南及其对移民和旅行者的适用性。
PAHO 建议使用两种血清学检测方法来诊断慢性感染(允许使用一种敏感检测方法,然后在特殊情况下进行确认,如潜在献血者的筛查)。急性感染的特定杀锥虫治疗的适应证,包括儿童和育龄妇女,与以前一样,贝那唑嗪或硝呋替莫是首选治疗药物。对于有/无器官损伤的慢性感染,治疗建议的定义不太明确。尽管一般不建议对有内脏受累的患者进行治疗,但需要根据个体情况来决定是否进行治疗。可以使用贝那唑嗪或硝呋替莫进行初始治疗。
最近的 PAHO 指南为诊断和管理这种感染提供了一个框架,但在一些方面,如感染的漏诊、多学科的患者管理方法、疾病进展/治疗反应的新型生物标志物的研究以及新的治疗策略的开发等方面,仍需要进一步加强。